Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 15;20(1):35.
doi: 10.1186/s12885-019-6511-6.

Prognostic factors of patients with Gliomas - an analysis on 335 patients with Glioblastoma and other forms of Gliomas

Jianfeng Liang  1 , Xiaomin Lv  2 , Changyu Lu  1 , Xun Ye  1   3 , Xiaolin Chen  1   3 , Jia Fu  1 , Chenghua Luo  4 , Yuanli Zhao  5   6
Affiliations

Prognostic factors of patients with Gliomas - an analysis on 335 patients with Glioblastoma and other forms of Gliomas

Jianfeng Liang et al. BMC Cancer. .

Abstract

Background: The prognosis of glioma is poor, despite recent advances in diagnosis and treatment of the disease. It is important to investigate the clinical characteristics and prognostic factors of glioma so as to provide basis for treatment and management of patients.

Method: A total of 335 patients with glioma were included in this study. These patients were admitted to the medical center between November 2015 and December 2018. The clinical data, including demographic data, tumor characteristics, treatment strategy, expression pattern of tumor markers, and survival data, were retrospectively reviewed. Survival data were analyzed using Kaplan-Meier curves with log-rank test, while multivariate analysis Cox regression model was used to investigate risk factors for mortality.

Results: In this patient cohort, glioblastoma (40%), diffuse glioma (14.6%) and oligodendroglioma (9.6%) were the most common pathological types. The expression of Ki-67 was associated with several clinicopathological parameters (e.g. tumor type, grade, and number of lesions). In addition, Ki-67 correlated with the mortality within the first year of the post-treatment follow-up (P < 0.001). Kaplan-Maier analysis revealed that older patients (≥ 45 years) displayed worse prognosis than those aged under 45 years (P = 0.038). Dismal prognosis was also associated with clinical parameters, including high tumor grade, multiple lesions, and Karnofsky performance score (KPS). Multivariate analysis showed that low KPS (< 85) increased the risk of mortality by 2.3 folds with a 95% CI of 1.141 to 4.776 (P = 0.020). Low tumor grade (grade 1-2) oppositely reduced the mortality risk by 0.22 folds (95% CI, 0.065 to 0.763, P = 0.0168).

Conclusion: KPS and tumor grade were independent prognostic factors in patients with gliomas.

Keywords: Clinical characteristics; Glioblastoma; Gliomas; Prognostic factors; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Kaplan-Meier analysis showing the significant difference in survival between glioma patients with low and high Ki-67 expression
Fig. 2
Fig. 2
Significant association of clinical parameters with the overall survival of glioma patients as examined by Kaplan-Meier analysis
See this image and copyright information in PMC

References

    1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–543. doi: 10.1016/S1470-2045(01)00486-7. - DOI - PubMed
    1. Turner JD, Williamson R, Almefty KK, et al. The many roles of microRNAs in brain tumor biology. Neurosurg Focus. 2010;28:E3. doi: 10.3171/2009.10.FOCUS09207. - DOI - PubMed
    1. Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol, Biomark Prev : Publication Am Assoc Cancer Res, Cosponsored Am Soc Prev Oncol. 2014;23:1985–1996. doi: 10.1158/1055-9965.EPI-14-0275. - DOI - PMC - PubMed
    1. Chen S, Tanaka S, Giannini C, et al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neuro-Oncol. 2013;112:267–275. doi: 10.1007/s11060-013-1058-x. - DOI - PMC - PubMed
    1. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for Glioblastoma: a randomized clinical trial. JAMA. 2015;314:2535–2543. doi: 10.1001/jama.2015.16669. - DOI - PubMed

LinkOut - more resources